title: Anderson-Fabry disease and the heart.
abstract: Anderson-Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations of the GLA gene that encodes alpha-galactosidase A. The ensuing enzyme deficiency results in intracellular accumulation of neutral glycosphingolipids (primarily globotriaosylceramide) and progressive renal, cardiac, and cerebrovascular disease. Female carriers are at risk of developing disease, but this tends to be milder and more slowly progressive than in males. Left ventricular hypertrophy is the most common cardiac manifestation followed by conduction system disease, valve dysfunction, and arrhythmias. Management of cardiovascular symptoms and the prevention of complications rely on conventional pharmacologic and device-based therapies, but data on the effect of enzyme replacement therapy suggest that it has the potential to attenuate and possibly reverse some aspects of cardiac involvement.
authors.affiliation: Inherited Cardiac Diseases Unit, The Heart Hospital, University College London, UK.
authors.forename: Constantinos
authors.initials: C
authors.lastname: O'Mahony
authors.forename: Perry
authors.initials: P
authors.lastname: Elliott
mesh_terms: D000328:Adult; D001145:Arrhythmias, Cardiac / Q000235:genetics; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003952:Diagnostic Imaging; D018450:Disease Progression; D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000150:complications / Q000175:diagnosis / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D005260:Female; D020022:Genetic Predisposition to Disease; D006331:Heart Diseases / Q000175:diagnosis / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics* / Q000517:prevention & control / Q000628:therapy; D006334:Heart Function Tests; D006349:Heart Valve Diseases / Q000235:genetics; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D012307:Risk Factors; D012737:Sex Factors; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D002317:Cardiovascular Agents; D000519:alpha-Galactosidase